共 50 条
- [1] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I studyCANCER RESEARCH, 2024, 84 (07)Beecroft, ClaireGao, BoPark, JohnWilkinson, KateZhang, KarlYan, XiangyunLv, Yuan
- [2] Evaluation of the safety, pharmacokinetics, and efficacy of JS']JSKN003 in patients with advanced solid tumors: A phase I/II clinical study.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Liu, XiaojunZhang, JianShen, LinLiu, JieqiongHuang, JianZhuang, ZhixiangYin, YongmeiWang, XiangWang, XianWu, Jiong
- [3] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumorsCANCER SCIENCE, 2016, 107 (10) : 1477 - 1483Minami, HironobuAndo, YuichiMa, Brigette Buig YueLee, Jih-HsiangMomota, HiroyukiFujiwara, YutakaLi, LeungFukino, KoichiIto, KojiTajima, TakeshiMori, AsukaLin, Chia-Chi
- [4] A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid TumorsCLINICAL CANCER RESEARCH, 2014, 20 (07) : 1900 - 1909Rodon, JordiTawbi, Hussein A.Thomas, Anne L.Stoller, Ronald G.Turtschi, Christian P.Baselga, JoseSarantopoulos, JohnMahalingam, DevalingamShou, YapingMoles, Melissa A.Yang, LinGranvil, CamilleHurh, EunjuRose, Kristine L.Amakye, Dereck D.Dummer, ReinhardMita, Alain C.
- [5] A phase I, first-in-human, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-1287 administered daily to patients with advanced solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Ben GeorgeRichards, Donald A.Edenfield, William JefforyWarner, Steven L.Mouritsen, LarsBishop, ReynaAnthony, Stephen PatrickBearss, DavidVogelzang, Nicholas J.Whatcott, Clifford
- [6] Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a studyJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Moore, Kathleen N.Sabanathan, DhanushaDu, YiqunDuan, HuaxinLi, XiuminWang, FengMarathe, OmkarYang, HuaMakker, VickyGrowdon, WhitfieldCoward, JimZhao, PengLiu, LimingShi, RongLiu, ShengxueGu, WeiQiu, YangZhu, ZhongyuanZhang, JianHamilton, Erika P.
- [7] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid TumorsONCOLOGIST, 2019, 24 (04): : 455 - E121Bendell, Johanna C.Patel, Manish R.Moore, Kathleen N.Chua, Cynthia C.Arkenau, Hendrik-TobiasDukart, GaryHarrow, KimLiang, Chris
- [8] A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab ± oleclumab in advanced solid tumoursANNALS OF ONCOLOGY, 2020, 31 : S728 - S729Powderly, J.Bendell, J. C.Carneiro, B. A.Italiano, A.Macarulla Mercade, T.Castanon Alvarez, E.Imbimbo, M.Massard, C.Mueller, N.Gasco-Hernandez, A.
- [9] A phase 1, first-in-human, open-label, dose escalation and dose expansion study of TST005 in patients with locally advanced or metastatic solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Tolcher, Anthony W.Wu, XiaohuaZhang, JianBarve, Minal A.Gabrail, Nashat Y.Sommerhalder, DavidRivera, Ildefonso I. RodriguezWilks, SharonWu, YongLiu, RujiaoGao, ShuipingValiyil, AkhilkrishnaSayi, NtombizodwaGerma, CarolineQi, CharlieChen, LeiYu, StevenYao, JennyZhu, Xuelian
- [10] Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 studyLANCET ONCOLOGY, 2015, 16 (09): : 1133 - 1142Reid, TonyOronsky, BryanScicinski, JanScribner, Curt L.Knox, Susan J.Ning, ShouchengPeehl, Donna M.Korn, RonStirn, MeaghanCarter, Corey A.Oronsky, ArnoldTaylor, Michael J.Fitch, William L.Cabrales, PedroKim, Michelle M.Burris, Howard A.Lao, Christopher D.Abrouk, Nacer E. D.Fanger, Gary R.Infante, Jeffrey R.